Request 1

In the period of financial year to date:

How many individual funding requests for the usage of Infliximab in the treatment of Hidradentis Suppurativa has the CCG received? 

Of the above, is it possible to say how may have been approved? 

Response 1

We have had no requests for Infliximab for Rotherham CCG this financial year. 

Request 2

Are there any gainshare agreements in place between the CCG and a provider (e.g. hospital trust)?

If “Yes”, then please provide the following details: 

Response 2

Yes Infliximab and etanercept 

if patients are switched to an alternative bio similar The Rotherham Foundation Trust retain 80% of the savings the gain share runs 12months only April 2106 to March 2017. 

Request 3

Have any gainshare agreements been terminated, and if so which disease areas?

Response 3

No